You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR073/#425  Senaparib, a PARP inhibitor, in patients with BRCA1/2 mutated platinum sensitive recurrent ovarian cancer: subgroup analysis from Sabrina study

Article Text

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR073/#425  Senaparib, a PARP inhibitor, in patients with BRCA1/2 mutated platinum sensitive recurrent ovarian cancer: subgroup analysis from Sabrina study
Free
  1. Xiaohua Wu1,
  2. Jihong Liu2,
  3. Li Wang3,
  4. Zhongqiu Lin4,
  5. Jing Wang5,
  6. Chunyan Wang6,
  7. Beihua Kong7,
  8. Zhiqing Liang8,
  9. Ying Cheng9,
  10. Hongwu Wen10,
  11. Ge Lou11,
  12. Yi Huang12,
  13. Ke Wang13,
  14. Ruifang An14,
  15. Xianqing Zhu15,
  16. Huaijun Zhou16 and
  17. Ying Yue17
  1. 1Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China
  2. 2Sun Yat-sen University Cancer Center, Department of Gynecologic Oncology, guangzhou, China
  3. 3Henan Cancer Hospital, Department of Gynecologic Oncology, Zhengzhou, China
  4. 4Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Department of Gynecologic Oncology, Guangzhou, China
  5. 5Hu’nan Cancer Hospital, Department of Gynecologic Oncology, Changsha, China
  6. 6Liaoning Cancer Hospital, Department of Gynecologic Oncology, Shenyang, China
  7. 7Qilu hospital of Shandong University, Obstetrics and Gynecology, Jinan, Shandong province, China
  8. 8The Southwest Hospital of AMU, Department of Gynecologic Oncology, Chongqing, China
  9. 9Jilin Cancer Hospital, Department of Oncology, Changchun, China
  10. 10Peking Universtiy First Hospital, Department of Oncology, Beijing, China
  11. 11Harbin Medical University Cancer Hospital, Gynecological Oncology, Harbin, China
  12. 12Hubei Cancer Hospital, Department of Gynecologic Oncology, Wuhan, China
  13. 13Tianjin Cancer Hospital, Department of Gynecologic Oncology, Tianjin, China
  14. 14The First Affiliated Hospital of Xi’an Jiao Tong University, Department of Gynecologic Oncology, Xi’an, China
  15. 15Zhejiang Cancer Hospital, Department of Gynecologic Oncology, Hangzhou, China
  16. 16Nanjing Drum Tower Hospital, Department of Oncology, Nanjing, China
  17. 17First Hospital of Jilin University, Department of Gynecologic Oncology, Changchun, China

Abstract

Introduction Senaparib (IMP4297) showed promising antitumor activity for advanced ovarian cancer (OC). This study aimed to evaluate the efficacy and safety of senaparib in patients(pts) with BRCA1/2 mutated platinum sensitive recurrent OC. Here we assessed the efficacy by prior therapies and types of platinum sensitive.

Methods This open label, multicenter, single arm, phase II study (NCT04089189) enrolled recurrent OC pts with germline and/or somatic BRCA mutation who had previously received ≥ 2 lines of platinum-based chemotherapy(CT). Senaparib (100 mg oral QD) was administered until disease progression or unacceptable toxicity. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR) per RECIST v1.1.

Results As of 30 Jan 2023, 93 pts were enrolled. 59%/41% pts were partially/fully platinum sensitive. Median lines of prior systemic chemotherapy(CT) was 2 (range 2–7), and 71%/29% received 2/≥ 3 lines of CT. After a median follow up of 15.7 months, efficacy was assessed in 91 pts who received treatment of senaparib and ≥ 1 tumor evaluated and met the criteria for the response evaluable set. IRC had not finished the assessment and the efficacy assessed by investigators was showed in table 1.

Conclusion/Implications Senaparib demonstrated clinically meaningful antitumor activity in OC pts of fully or partially platinum sensitive who had previously received ≥ 2 lines of CT.

View this table:
Abstract PR073/#425 Table 1

https://doi.org/10.1136/ijgc-2023-IGCS.113

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.